- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 2277
10-year publication summary
|
146
|
164
|
176
|
158
|
237
|
254
|
202
|
175
|
187
|
73
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 340 |
138 |
| Regeneron Pharmaceuticals, Inc. | 4701 |
126 |
| Amgen Inc. | 4427 |
35 |
| The Regents of the University of California | 20745 |
34 |
| Keros Therapeutics, Inc. | 81 |
32 |
| Immatics Biotechnologies GmbH | 1127 |
31 |
| The Trustees of the University of Pennsylvania | 4415 |
25 |
| Board of Regents, The University of Texas System | 6107 |
22 |
| Immunitybio, Inc. | 507 |
21 |
| The Board of Trustees of the Leland Stanford Junior University | 6653 |
20 |
| City of Hope | 1030 |
20 |
| Precigen Inc | 107 |
20 |
| Genentech, Inc. | 4104 |
19 |
| Genzyme Corporation | 1368 |
19 |
| The Johns Hopkins University | 5882 |
18 |
| Biocon Limited | 221 |
17 |
| Seattle Children's Hospital | 92 |
17 |
| Novartis AG | 10262 |
14 |
| Levicept Ltd | 30 |
14 |
| National Research Council of Canada | 1551 |
14 |
| Other owners | 1621 |